Pharmacological blockade of 2-AG degradation ameliorates clinical, neuroinflammatory and synaptic alterations in experimental autoimmune encephalomyelitis

In conclusion, MAGL inhibition significantly ameliorated EAE clinical disability and striatal inflammatory synaptopathy through potent anti-inflammatory effects. These findings provide new mechanistic insights into the neuroprotective role of the ECS during neuroinflammation and highlight the therapeutic potential of MAGLi-based drugs in mitigating MS-related inflammatory and neurodegenerative brain damage.PMID:38570068 | DOI:10.1016/j.neuropharm.2024.109940

Source: Neuropharmacology - April 3, 2024 Category: Drugs & Pharmacology Authors: Livia Guadalupi Georgia Mandolesi Valentina Vanni Sara Balletta Silvia Caioli Anto Pavlovic Francesca De Vito Diego Fresegna Krizia Sanna Laura Vitiello Monica Nencini Alice Tartacca Fabrizio Mariani Valentina Rovella Sven Schippling Iris Ruf Ludovic Coll Source Type: research